TSC1 involvement in bladder cancer: diverse effects and therapeutic implications (Q39196241)

9 September 2017

title

TSC1 involvement in bladder cancer: diverse effects and therapeutic implications (English)

1 reference

9 September 2017

0 references

1 reference

5

Nathanael S Gray

1 reference

9 September 2017

Yanan Guo

1

1 reference

9 September 2017

Yvonne Chekaluk

2

1 reference

9 September 2017

Jianming Zhang

3

1 reference

9 September 2017

Jinyan Du

4

1 reference

9 September 2017

Chin-Lee Wu

6

1 reference

9 September 2017

David J Kwiatkowski

7

1 reference

9 September 2017

publication date

21 March 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

230

1 reference

9 September 2017

issue

1

1 reference

9 September 2017

page(s)

17-27

1 reference

describes a project that uses

9 September 2017

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

Cancer statistics, 2012

1 reference

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

21 January 2018

1 reference

Epidemiology and genetic susceptibility to bladder cancer

21 January 2018

1 reference

Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer.

21 January 2018

1 reference

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

21 January 2018

1 reference

Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms

21 January 2018

1 reference

Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium

21 January 2018

1 reference

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

21 January 2018

1 reference

Transcriptional control of cellular metabolism by mTOR signaling

21 January 2018

1 reference

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

21 January 2018

1 reference

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

21 January 2018

1 reference

TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase.

21 January 2018

1 reference

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR

21 January 2018

1 reference

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

21 January 2018

1 reference

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

21 January 2018

1 reference

Profiling critical cancer gene mutations in clinical tumor samples

21 January 2018

1 reference

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis

21 January 2018

1 reference

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis

21 January 2018

1 reference

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms

21 January 2018

1 reference

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

21 January 2018

1 reference

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

21 January 2018

1 reference

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

21 January 2018

1 reference

Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis

21 January 2018

1 reference

Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner

21 January 2018

1 reference

High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PATH.4176

1 reference

9 September 2017

1 reference